


Response to Restriction Requirement
USSN 10/787,921


Attorney Docket R0162B-RFG

CLAIM LISTING:

1. (Currently amended) A compound having the formula:



wherein



T is

where R^6 is taken together with one of R^7 and R^8 to form a bridge of one to two bridgehead carbon atoms, and the other of R^7 and R^8 is selected from hydrogen and R^9 ;

Ar and Ar^1 are, independently of each other, phenyl, ether, aryl or heteroaryl;

F is alkylene, alkenylene, or a bond;

E is selected from $-\text{C}(=\text{O})\text{N}(\text{R}^{10})-$, $-\text{SO}_2\text{N}(\text{R}^{10})-$, $-\text{N}(\text{R}^{11})\text{C}(=\text{O})\text{N}(\text{R}^{10})-$, $-\text{N}(\text{R}^{11})\text{SO}_2\text{N}(\text{R}^{10})-$, $-\text{N}(\text{R}^{11})\text{C}(-\text{S})\text{N}(\text{R}^{11})-$, $-\text{N}(\text{R}^{11})\text{C}(=\text{O})-$, $-\text{N}(\text{R}^{11})\text{SO}_2-$, $-\text{N}(\text{R}^{12})\text{C}(=\text{O})\text{CH}(\text{R}^{13})-$, and

$\text{CH}(\text{R}^{13})\text{C}(=\text{O})\text{N}(\text{R}^{12})-$, where:

R^{10} , R^{11} , R^{12} , and R^{13} are, independently of each other, hydrogen, alkyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heteroalkyl, or -(alkylene)- $\text{C}(=\text{O})\text{Z}$, where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy; or alternatively, R^{12} and R^{13} may be taken together with the nitrogen and carbon atoms to which they are attached, respectively, to form a heterocyclol or heteroaryl ring optionally substituted with up to two groups selected from R^{14} ;

R^3 and R^4 are, independently of each other, hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclol, heterocyclylalkyl, heteroalkyl, -(alkylene)- $\text{C}(=\text{O})\text{Z}^1$, or -(alkylene)- $\text{C}(\text{O})_2\text{Z}^1$, where Z^1 is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy;

R^5 is hydrogen or alkyl;

Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162B-RUG

Q is $-C(=O)-$ or $C_{1-2}alkylene$;

R^9 is attached to any available carbon atom of ring T and is selected from lower alkyl, hydroxy, lower alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, or a lower alkyl substituted with one of hydroxy, lower alkoxy, halo, cyano, trifluoromethyl, or trifluoromethoxy;

R^{14} is selected from lower alkyl, hydroxy, lower alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, and a lower alkyl substituted with one of hydroxy, lower alkoxy, halo, cyano, trifluoromethyl, or trifluoromethoxy;

m is 0 or 1; and

n is 0 to 4; and

~~prodrug, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof.~~

2. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt or ~~prodrug~~ thereof, wherein:

Ar and Ar^1 are both phenyl;

F is a bond;

E is selected from $-C(=O)N(R^{10})-$, $-N(R^{11})C(=O)N(R^{10})-$, $-N(R^{11})C(=O)-$, $-N(R^{12})C(=O)CH(R^{13})-$, and $CH(R^{13})C(=O)N(R^{12})-$, where:

R^{10} , R^{11} , R^{12} , and R^{13} are, independently of each other, hydrogen or alkyl;

or alternatively, R^{12} and R^{13} may be taken together with the nitrogen and carbon atoms to which they are attached, respectively, to form a heterocyclic or heteroaryl ring optionally substituted with up to two groups selected from R^{14} ;

R^3 and R^4 are, independently of each other, hydrogen, alkyl, alkynyl, haloalkyl, heteroalkyl, or $-(alkylene)-C(=O)-Z^1$, where Z^1 is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy;

Q is $-CH_2-$;


R^9 and R^{14} are independently selected from methyl, ethyl, hydroxy, methoxy, halo, cyano, trifluoromethyl, or trifluoromethoxy; and

n is 0 to 2.

Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162B-RFG

3. (Currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein T is selected from the group consisting of:



and R⁹ is attached to any available carbon atom of ring T and is selected from lower alkyl and hydroxy, and n is 0 to 2.

4. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar is a phenyl ring optionally substituted with one, two or three substituents selected from alkyl, heteroalkyl, alkoxy, -COR¹⁵, -SO₂R¹⁷, methylenedioxy, hydroxy, halo, acylamino, amino, mono- or disubstituted amino, -CONR¹⁵R¹⁶, -(alkylene)-CONR¹⁵R¹⁶, -COOR¹⁵, -(alkylcyclo)-COOR¹⁵ and/or -NR¹⁶SO₂R¹⁷;
R¹⁵ and R¹⁶ are each independently hydrogen or alkyl; and
R¹⁷ is alkyl, amino or mono or disubstituted amino.

5. (Currently amended) A compound of claim 4, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Ar is selected from phenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-methylsulfonylphenyl, 3,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,4,5-trimethoxyphenyl.


6. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein F is a bond.

Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162B-REG


7. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein

E is $-\text{C}(=\text{O})\text{N}(\text{R}^{10})-$, $-\text{N}(\text{R}^{10})\text{C}(=\text{O})\text{N}(\text{R}^{11})-$, or $\text{N}(\text{R}^{12})\text{C}(=\text{O})\text{CH}(\text{R}^{13})-$, where R^{10} and R^{11} are hydrogen or lower alkyl, and R^{12} and R^{13} are taken together with the nitrogen and carbon atoms to



which they are attached, respectively, to form ; where R^{18} and R^{19} are selected from hydrogen and lower alkyl.

8. (Currently amended) A compound of claim 7, or a pharmaceutically acceptable salt or prodrug thereof, wherein



E is ; and m is 0.

9. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein

R^3 is hydrogen; and

R^4 is hydrogen, methyl, ethyl, 1-methylethyl, isopropyl, 1-hydroxyethyl or 2-hydroxyethyl.


10. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein

R^3 is hydrogen; and R^4 is 1-methylethyl.

Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162R-REG

11. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein T is



12. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein Q is $-\text{CH}_2-$.


13. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar^1 is a phenyl ring optionally substituted with one, two or three substituent selected from alkyl, heteroalkyl, alkoxy, halo, trifluoromethyl, nitro, or mono- or disubstituted amino.

14. (Currently amended) A compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar^1 is 4-chlorophenyl or 3,4-dichlorophenyl.


15. (Original) A compound having the formula (II):



or a pharmaceutically-acceptable salt thereof, in which:

Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162D-REG



T is , where R⁶ is taken together with one of R⁷ and R⁸ to form a bridge of one to two bridgehead carbon atoms optionally substituted with one to two CH₃, and the other of R⁷ and R⁸ is selected from hydrogen and lower alkyl;

E is selected from -C(=O)N(R¹⁰)-, -N(R¹¹)C(-O)N(R¹⁰)-, and -N(R¹²)C(=O)CH(R¹³)-, where:

R¹⁰, R¹¹, R¹², and R¹³ are independently of each other hydrogen or lower alkyl, or alternatively, R¹² and R¹³ may be taken together with the nitrogen and carbon atoms to which they are attached, respectively, to form a five-membered heterocyclyl or heteroaryl ring having up to two N atoms and optionally substituted with up to two groups selected from methyl, ethyl, hydroxy, methoxy, halo, cyano, trifluoromethyl, and trifluoromethoxy;


R⁴ is hydrogen, lower alkyl, or lower alkyl substituted with hydroxy;

R²⁰ and R²¹ are each independently selected from halo, OR²², and SO₂R²², wherein R²² is lower alkyl;

m is 0 or 1;

p and q are independently 0, 1, 2 or 3.

16. (Currently amended) A compound of claim 15, or a pharmaceutically acceptable salt or prodrug thereof, wherein



E is selected from -C(=O)NH-, -NHC(=O)NH-, and are each hydrogen or lower alkyl;

R⁴ is hydrogen, methyl, ethyl, 1-hydroxyethyl, or 1-methylethyl;


Response to Restriction Requirement
USSN 10/787,921

Attorney Docket R0162B-REG

R^6 is taken together with one of R^7 and R^8 to form a bridge of two bridgehead carbon atoms and the other of R^7 and R^8 is hydrogen;
 R^{20} is selected from halo, methoxy, and methylsulfonyl;
 R^{21} is halo;
 p is 0, 1, 2 or 3; and
 q is 0, 1, or 2.

17. (Currently amended) A compound of claim 16, or a pharmaceutically acceptable salt

or prodrug thereof, wherein T is



18. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.

19-20. Canceled.

* * * * *